The research for antitumor therapeutics is a timeless topic and keeps pace with times, especially chemotherapy and target therapy. Drug target identification is a key step in the development of effective therapeutic agents. In this issue, we present the current status of some validated and potential targets in drug discovery for developing therapeutic agents as well as some novel compounds for the treatment of cancer. I am indebted to my colleagues for their cooperation and efforts to find time from their busy schedule to contribute to this issue. Also I would like to thank, on behalf of all the contributors, the journal for providing us an opportunity to share our thoughts on these interesting topics and hope this issue will benefit research scientists in their pursues related to these topics.

The first article, from Zui Pan and colleagues, summarizes some important Ca^2+^ channels, transporters and Ca^2+^-ATPases, which have been reported to be altered in human cancer patients. It discusses the current research effort toward evaluation of the blockers, inhibitors or regulators for Ca^2+^ channel/transporter or Ca^2+^-ATPase pump as anti-cancer drugs. It poses that targeting Ca^2+^ channels or transporters could be novel therapies to cure malignancies.

Defects in apoptotic machinery are one of the main mechanisms that cells employ to evade cell death and become cancerous. Targeting the apoptotic defects, can restore cell sensitivity to cell death. The review from Jing Deng focused on the aspects of BCL-2 family proteins, demonstrated some potential novel targeted agents to overcome the apoptotic blockades and reported that BH3 profiling may be a factor to predict responses to chemotherapies.

The PI3K/AKT/mTOR pathway is an intracellular signaling pathway important in regulating the cell cycle. Amounts of PI3K inhibitors sprung up recently, multifaceted studies on these PI3K inhibitors are being performed, such as single and combinational efficacy, resistance, biomarkers, etc. Dexin Kong provides an overview of key advances in the development of PI3K inhibitors.

Multidrug resistance remains a major clinical obstacle to successful cancer treatment and the exact mechanisms of MDR are poorly understood. Hua Zhu and colleagues provide a review on the role of microRNAs in regulating MDR through various drug resistant mechanisms, thereby holding much promise for developing novel and more effective individualized therapies for cancer treatment.

Related to cancer treatment, traditional Chinese drug extract also plays an important role. Jianye Zhang׳s laboratory demonstrated that Euphorbia factor L2, a lathyrane diterpenoid isolated from caper euphorbia seed could induce apoptosis in lung carcinoma A549 cells through a mitochondrial pathway. And Xixu Zhu group investigated the efficacy and mechanism of action of asiatic acid, a pentacyclic triterpene found in *Centella asiatica*, against lung cancer both *in vitro* and *in vivo*. They found that asiatic acid resulted in collapse of the mitochondrial membrane potential and generation of reactive oxygen species (ROS) *in vivo* and the associated apoptosis is mediated through mitochondrial damage.

In addition to searching for new anti-cancer target, the synthesis of new compounds by incorporating pharmacophore into traditional drugs to enhance their effects and developing new *in situ* drug delivery system to avoid unnecessary adverse effect are also nice choices. Two articles are devoted to it. One is provided by Amit K. Tiwari and colleagues with a focus on 2,3-diaryl-3*H*-imidazo\[4,5-*b*\]pyridine. Eight 2,3-diaryl-3*H*-imidazo\[4,5-*b*\]pyridine derivatives showed modest cytotoxic activity against cancer cell lines and possess COX-1 and COX-2 inhibitory activity *in vitro*. And Yiguang Jin and colleagues prepared an inhalable oridonin-loaded poly(lactic-*co*-glycolic)acid (PLGA) large porous microparticle (LPMP) for *in situ* treatment of NSCLC with the emulsion/solvent evaporation/freeze-drying method. The LPMPs showed strong anticancer effects by inducing mitochondrial dysfunction accompanied by lowing mitochondrial membrane potentials, downregulation of BCL-2 expressions, upregulation of expressions of BAX, caspase-3 and caspase-9.

Finally, there is a short commutation by Jianhua Xu, he presented the strongest affinity between 3,5-(*E*)-bis(3-methoxy-4-hydroxybenzal)-4-piperidinone hydrochloride (C0818) and heat shock protein 90 (Hsp90). It conclusively demonstrates that inhibitory activity of C0818 could affect the activity of Hsp90 ATPase.

I hope this issue provides our readers a comprehensive background and current views on the presented topics, and helps researchers in their search for effective therapeutic agents, as well as stimulates further research interests to move the fields forward.
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